Psyence Biomedical Ltd. (NASDAQ:PBM – Get Free Report)’s share price was up 7.9% on Thursday . The company traded as high as $1.82 and last traded at $1.77. Approximately 181,792 shares changed hands during trading, a decline of 61% from the average daily volume of 460,805 shares. The stock had previously closed at $1.64.
Psyence Biomedical Stock Up 1.1 %
The firm has a 50 day simple moving average of $2.68 and a two-hundred day simple moving average of $14.62.
About Psyence Biomedical
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.
Read More
- Five stocks we like better than Psyence Biomedical
- What Are Earnings Reports?
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- How to Invest in Small Cap Stocks
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- High Dividend REITs: Are They an Ideal Way to Diversify?
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for Psyence Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psyence Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
